文献速递免疫规划传染病防控与疫情报告

减毒结核分枝杆菌疫苗MTBVAC在结核分枝杆菌致敏与非致敏成人中的单中心1b-2a期双盲剂量递增随机对照试验

Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial.
PubMed 文献 · Lancet Glob Health · 2025-04-15

该单中心1b-2a期双盲剂量递增随机对照试验纳入144名已接种卡介苗的南非成人,按2:1随机接受不同剂量MTBVAC或卡介苗复种。结果显示MTBVAC 5×10^5 CFU剂量安全性与卡介苗相似且免疫原性更高,作者认为该剂量可被选择用于后续效力评价。

要点

  • MTBVAC注射部位疼痛、分泌物、红斑和肿胀随剂量水平增加。
  • MTBVAC 5×10^5 CFU组相关不良事件比例与卡介苗组相似(23/24 vs 45/47)。
  • QFT阳性MTBVAC受者注射部位反应多于QFT阴性受者(46/48 vs 32/48)。

核心结论

  • MTBVAC在5×10^5剂量下与卡介苗相比显示相似的安全性和反应原性以及更高的免疫原性。
  • 作者认为这些结果提示5×10^5剂量的MTBVAC可被选择用于后续效力评价。

研究设计与样本

  • 单中心、1b-2a期、双盲、剂量递增、随机对照试验(NCT02933281)。
  • 纳入已接种卡介苗、HIV阴性、年龄18-50岁的南非成人,经QuantiFERON-结核金Plus检测有或无结核分枝杆菌致敏。
  • 参与者按2:1随机分配接受MTBVAC(5×10^3、5×10^4、5×10^5或5×10^6 CFU剂量)或卡介苗复种(5×10^5 CFU剂量)。
  • 主要结局为接种后7天内全身性征集性不良事件、28天内非征集性不良事件、84天内征集性和非征集性注射部位反应,以及至研究结束(接种后365天)的严重不良事件。
  • 数据按改良意向性治疗分析。

主要发现

  • 2019年1月15日至2020年9月7日期间,485名参与者签署知情同意并接受筛查,144名入组,143名(99%)接种。
  • 143名接种者中47名(33%)接受卡介苗,96名(67%)接受MTBVAC。
  • 12名QFT阴性者和12名QFT阳性者被随机分配接受各剂量MTBVAC,24名QFT阴性者和24名QFT阳性者被随机分配接受卡介苗复种。
  • MTBVAC注射部位疼痛、分泌物、红斑和肿胀随MTBVAC剂量水平增加。
  • MTBVAC 5×10^5 CFU受者报告的相关不良事件比例与卡介苗受者相似(23/24[96%] vs 45/47[96%])。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An effective adult vaccine is needed to control tuberculosis. We evaluated the safety and immunogenicity of a live-attenuated Mycobacterium tuberculosis vaccine (MTBVAC). METHODS: This single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial (NCT02933281) enrolled South African adults previously vaccinated with BCG, who were HIV negative and aged 18-50 years, with or without M tuberculosis sensitisation assessed by QuantiFERON-tuberculosis Gold-Plus assay (QFT). Participants were recruited from the local community and randomly allocated (2:1) to receive MTBVAC (5 × 103, 5 × 104, 5 × 105, or 5 × 106 colony-forming unit [CFU] doses) or BCG revaccination (5 × 105 CFU dose). The primary outcomes were the occurrence of systemic solicited adverse events within 7 days and unsolicited adverse events within 28 days after vaccination, the occurrence of solicited and unsolicited injection-site reactions within 84 days after vaccination, and the occurrence of serious adverse events (SAEs) until the end of study, 365 days after vaccination. Data were analysed per modified intention to treat. The trial is now complete and closed. FINDINGS: Between Jan 15, 2019, and Sept 7, 2020, 485 participants provided consent and were screened. 144 participants were enrolled and 143 (99%) were vaccinated. BCG was administrated to 47 (33%) of 143 and MTBVAC to 96 (67%) of 143. 12 participants with QFT-negative results and 12 with QFT-positive results were randomly allocated to receive each dose of MTBVAC and 24 participants with QFT-negative results and 24 with QFT-positive results were randomly allocated to receive BCG revaccination. Injection-site pain, discharge, erythema, and swelling increased with MTBVAC dose level. MTBVAC 5 × 105 CFU recipients reported a similar proportion of related adverse events (23 [96%] of 24) as BCG recipients (45 [96%] of 47). MTBVAC recipients who were QFT positive reported more injection-site reactions (46 [96%] of 48; 95% CI 85·7-99·5) than MTBVAC recipients who were QFT negative (32 [67%] of 48; 51·6-79·6). No vaccine-related SAEs were reported. All doses of MTBVAC were immunogenic; vaccine-induced antigen-specific CD4 T-cell responses peaked 28 days after vaccination. The MTBVAC 5 × 105 and 5 × 106 CFU doses induced T-helper-cell-1 cytokine-expressing CD4 T-cell responses that exceeded BCG-induced responses in participants who were QFT negative and QFT positive. INTERPRETATION: MTBVAC at the 5 × 105 dose showed similar safety and reactogenicity and greater immunogenicity when compared to BCG. These results suggest that the 5 × 105 dose of MTBVAC could be selected for a subsequent efficacy evaluation. FUNDING: Congressionally Directed Medical Research Programmes and US National Institutes of Health.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Luabeya AKK, Rozot V, Imbratta C, et al. Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial. Lancet Glob Health. 2025. PMID: 40250461. doi:10.1016/S2214-109X(25)00046-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。